Overview

Anti-obesity nanotherapy development at Protheragen focuses on harnessing nanotechnology to develop targeted treatments for obesity by delivering therapeutic agents directly to adipose tissue or modulating metabolic pathways. This innovative approach aims to improve the effectiveness and reduce the side effects of traditional anti-obesity treatments by Specifically Targeting Areas involved in fat storage and metabolism.

Targeting Fat, Transforming Health-Protheragen's Nanotherapy for Lasting Obesity Solution

Our nanotherapy development focuses on key obesity-related targets, leveraging nanocarriers to address fat metabolism. One of the main targets is prohibitin, a protein on endothelial cells in white adipose tissue (WAT), which regulates fat metabolism. Nanocarriers are used to deliver pro-apoptotic agents to fat cells, inducing cell death and reducing fat tissue mass. Another target is VEGF and other angiogenic factors, which support the expansion of WAT by forming new blood vessels. Inhibiting these factors with nanoparticles (NPs) restricts blood flow to fat tissues, leading to reduced fat accumulation. Additionally, targeting peripheral Cannabinoid 1 (CB1) Receptors allows Protheragen to block fat storage without triggering the psychoactive effects associated with central CB1 antagonists. Lastly,  Uncoupling Protein 1 (UCP1), a marker for brown adipose tissue (BAT) thermogenesis, is targeted using NPs to promote the browning of WAT, enhancing fat-burning and metabolic activity.

Workflow

Target Discovery

The first phase of anti-obesity nanotherapy focuses on identifying key targets like WAT, BAT, and the Endocannabinoid system (ECS). Targeting WAT via prohibitin and VEGF inhibits angiogenesis to reduce fat accumulation, while NPs are used to transform WAT into energy-expending BAT. Nanotherapies also target peripheral CB1 receptors in the ECS to block fat storage without affecting the central nervous system.

Development of Nanocarriers

Protheragen employs nanocarriers, including liposomes, polymeric NPs, and gold NPs, to deliver anti-obesity agents directly to adipose tissues. These nanocarriers utilize passive targeting via the enhanced permeability and retention (EPR) effect to accumulate in adipose tissues and active targeting through ligand modifications, like prohibitin-homing peptides, ensuring precise delivery to receptors on endothelial cells in fat tissues.

Preclinical Studies

In preclinical studies, NPs are tested in diet-induced obese (DIO) animal models to assess their effectiveness in reducing body weight and fat mass. Techniques used include in vivo imaging (fluorescent or MRI) to track NP distribution, pharmacokinetics to study how long NPs remain in the bloodstream and their metabolism, and histological analysis to evaluate changes in adipose tissue structure and fat metabolism post-treatment.

Safety and Toxicity Studies

Safety is essential in nano-therapy development. Protheragen conducts thorough toxicity assessments, including immunogenicity testing to ensure nanocarriers don't trigger harmful immune responses, systemic toxicity studies to assess the impact on major organs like the liver, kidneys, and heart, and biocompatibility testing to confirm that the nanomaterials do not cause adverse reactions or toxicity in animal models.

Optimization and Scaling

After successful preclinical trials, Protheragen optimizes nanocarrier design for clinical use by enhancing drug-loading capacity to maximize therapeutic effects, improving nanocarrier stability for longer circulation and controlled drug release, and scaling production to meet the requirements for clinical trials and commercial production.

Applications

• Protheragen's nanotherapies deliver anti-obesity agents directly to adipose tissues, ensuring precise targeting of fat cells.
• By targeting key pathways such as WAT and promoting BAT browning, nanotherapies enhance fat burning and energy expenditure, aiding in effective weight loss.
• NPs can be used to trigger the transformation of WAT into BAT, promoting thermogenesis and fat burning as part of a targeted weight-loss strategy.
• Nanotherapy can be used in conjunction with other anti-obesity therapies, such as diet or pharmacological treatments, for enhanced efficacy and comprehensive weight management.

Advantages

• Protheragen's nanotherapies use advanced targeting methods, such as ligand-modified NPs, to precisely deliver treatments to fat tissues, ensuring a higher therapeutic impact with fewer side effects.
• By focusing on specific fat cell targets, nanotherapies limit systemic exposure, significantly reducing the risk of side effects commonly seen with traditional obesity treatments.
• Protheragen's nanocarriers enable controlled drug release, allowing for sustained therapeutic effects over time, which enhances the efficacy of anti-obesity treatments while requiring fewer doses.
• Nanotherapies provide a holistic approach by addressing both fat accumulation and energy expenditure.

Our Services

Nanotherapies offer groundbreaking approaches to obesity treatment. Protheragen supports this innovative field with services in tissue function analysis, inflammation studies, and metabolic pathway evaluations.

Frequently Asked Questions

What is anti-obesity nanotherapy?

Anti-obesity NPs and nanocarriers deliver therapeutic agents directly to adipose tissues (fat cells) to target fat accumulation and metabolism. These therapies are designed for precision targeting, enhancing fat burning, reducing fat storage, and improving metabolic health in patients with obesity.

What are the main biological targets of Protheragen's anti-obesity nanotherapy?

The primary targets include WAT, where fat is stored, and BAT, which promotes fat burning. Nanotherapies can also target the ECS, specifically CB1 receptors, to reduce fat storage and enhance energy balance.

Are there any side effects associated with nanotherapy?

Nanotherapy's targeted nature significantly reduces systemic side effects. Focusing treatment on adipose tissues, limits exposure to other organs, unlike traditional obesity treatments that can have broad effects on the body. However, comprehensive toxicity assessments are conducted to ensure safety, including studies on biocompatibility, immunogenicity, and systemic toxicity.

Publication

Discover the future of weight loss with Protheragen's anti-obesity nanotherapy development, offering precision-targeted, innovative solutions for effective and sustainable fat reduction. Please feel free to contact us for more information and to discuss more possibilities.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Anti-Obesity Antibody Therapy Development
• Anti-Obesity Cell Therapy Development
• Anti-Obesity Gene Therapy Development
• Anti-Obesity Small Molecule Drug Development
• Anti-Obesity Tissue Engineering Therapy Development